138 related articles for article (PubMed ID: 11725817)
1. Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies.
Sabbagh MN; Reid RT; Hansen LA; Alford M; Thal LJ
J Neural Transm (Vienna); 2001; 108(10):1149-57. PubMed ID: 11725817
[TBL] [Abstract][Full Text] [Related]
2. Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease.
Rei RT; Sabbagh MN; Corey-Bloom J; Tiraboschi P; Thal LJ
Neurobiol Aging; 2000; 21(5):741-6. PubMed ID: 11016544
[TBL] [Abstract][Full Text] [Related]
3. Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology.
Teaktong T; Graham AJ; Court JA; Perry RH; Jaros E; Johnson M; Hall R; Perry EK
J Neurol Sci; 2004 Oct; 225(1-2):39-49. PubMed ID: 15465084
[TBL] [Abstract][Full Text] [Related]
4. Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer's disease.
Marui W; Iseki E; Kato M; Akatsu H; Kosaka K
Acta Neuropathol; 2004 Aug; 108(2):121-8. PubMed ID: 15235805
[TBL] [Abstract][Full Text] [Related]
5. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies.
Kasanuki K; Iseki E; Fujishiro H; Yamamoto R; Higashi S; Minegishi M; Togo T; Katsuse O; Uchikado H; Furukawa Y; Hino H; Kosaka K; Sato K; Arai H
J Neurol Sci; 2012 Mar; 314(1-2):111-9. PubMed ID: 22041339
[TBL] [Abstract][Full Text] [Related]
6. Increased Transforming Growth Factor β2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Aβ42 Load.
Chong JR; Chai YL; Lee JH; Howlett D; Attems J; Ballard CG; Aarsland D; Francis PT; Chen CP; Lai MK
J Alzheimers Dis; 2017; 56(1):157-166. PubMed ID: 27911312
[TBL] [Abstract][Full Text] [Related]
7. Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease.
Sabbagh MN; Reid RT; Corey-Bloom J; Rao TS; Hansen LA; Alford M; Masliah E; Adem A; Lloyd GK; Thal LJ
J Neural Transm (Vienna); 1998; 105(6-7):709-17. PubMed ID: 9826113
[TBL] [Abstract][Full Text] [Related]
8. Neuropathological investigation of hypocretin expression in brains of dementia with Lewy bodies.
Kasanuki K; Iseki E; Kondo D; Fujishiro H; Minegishi M; Sato K; Katsuse O; Hino H; Kosaka K; Arai H
Neurosci Lett; 2014 May; 569():68-73. PubMed ID: 24704327
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
[TBL] [Abstract][Full Text] [Related]
10. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380.
Pimlott SL; Piggott M; Owens J; Greally E; Court JA; Jaros E; Perry RH; Perry EK; Wyper D
Neuropsychopharmacology; 2004 Jan; 29(1):108-16. PubMed ID: 12955099
[TBL] [Abstract][Full Text] [Related]
11. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging.
Sabbagh MN; Shah F; Reid RT; Sue L; Connor DJ; Peterson LK; Beach TG
Arch Neurol; 2006 Dec; 63(12):1771-6. PubMed ID: 17172618
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies.
Gómez-Isla T; Growdon WB; McNamara M; Newell K; Gómez-Tortosa E; Hedley-Whyte ET; Hyman BT
Neurology; 1999 Dec; 53(9):2003-9. PubMed ID: 10599772
[TBL] [Abstract][Full Text] [Related]
13. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies.
Tam CW; Burton EJ; McKeith IG; Burn DJ; O'Brien JT
Neurology; 2005 Mar; 64(5):861-5. PubMed ID: 15753423
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.
Jellinger KA; Attems J
Acta Neuropathol; 2008 Apr; 115(4):427-36. PubMed ID: 18273624
[TBL] [Abstract][Full Text] [Related]
15. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial.
Querfurth HW; Allam GJ; Geffroy MA; Schiff HB; Kaplan RF
Dement Geriatr Cogn Disord; 2000; 11(6):314-21. PubMed ID: 11044776
[TBL] [Abstract][Full Text] [Related]
16. Pathology and neurotransmitter abnormalities of dementia with Lewy bodies.
Duda JE
Dement Geriatr Cogn Disord; 2004; 17 Suppl 1():3-14. PubMed ID: 14676464
[TBL] [Abstract][Full Text] [Related]
17. Comparison between Alzheimer's disease and vascular dementia: implications for treatment.
Kalaria RN
Neurol Res; 2003 Sep; 25(6):661-4. PubMed ID: 14503021
[TBL] [Abstract][Full Text] [Related]
18. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies.
Szot P; White SS; Greenup JL; Leverenz JB; Peskind ER; Raskind MA
J Neurosci; 2006 Jan; 26(2):467-78. PubMed ID: 16407544
[TBL] [Abstract][Full Text] [Related]
19. Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies.
Klucken J; McLean PJ; Gomez-Tortosa E; Ingelsson M; Hyman BT
Neurochem Res; 2003 Nov; 28(11):1683-91. PubMed ID: 14584822
[TBL] [Abstract][Full Text] [Related]
20. Neurofibrillary pathology in Alzheimer disease with Lewy bodies: two subgroups.
Gearing M; Lynn M; Mirra SS
Arch Neurol; 1999 Feb; 56(2):203-8. PubMed ID: 10025425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
